15.03.2011 • News

U.S. Drug Prices Outstrip Other Medical Costs

U.S. prices for brand-name prescription drugs rose at a faster rate than costs for other medical goods and services over the last four years, according to a new U.S. government report.

The nonpartisan U.S. Government Accountability Office found that the "usual and customary" price index for the top 100 commonly used drugs increased by an annual average of 6.6% from 2006 through the first quarter of 2010, compared with a 3.8% average annual increase in the consumer price index for medical goods and services.

The basket of drugs contained 55 brand-name medicines and 45 generic drugs.

Prices for the brand-name drugs rose by an annual average of 8.3%, while prices for the generics fell by 2.6% annually, according to the report.

When looking at the 100-drug basket by active ingredient - meaning brand-name products and generics with the same active ingredient were considered as the same drug - the GAO found that prices rose by about 2.6% a year.

"This report reminds us that this is an area where we should be looking for savings for taxpayers and beneficiaries," said Democratic Rep. Pete Stark, a ranking member of the House Ways and Means subcommittee on health. The Pharmaceutical Research and Manufacturers of America said it was "pleased" that the GAO took into account the mix of brand and generic medicines that patients actually use.

"The report's key finding shows prices have been increasing at a rate of 2.6% annually, which is lower than overall medical inflation," the trade group said in a statement.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.